Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? AT1-receptor antagonists?
Hoppe
Uta C
UC
Department of Internal Medicine III, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany. uta.hoppe@uni-koeln.de
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D002303:Cardiac Output, Low / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D002908:Chronic Disease; D016757:Death, Sudden, Cardiac / Q000209:etiology / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications; D012084:Renin-Angiotensin System / Q000187:drug effects*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors